Form 8-K Valeant Pharmaceuticals For: Apr 29
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/17/2026
- Generac strikes $8B supply deal with Amazon for data center power
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Paradium AI (PAAI) Halted, News Pending
- Shipping stocks on fire — but cracks are forming in the rate rally
- JPMorgan Fed scenario analysis: 5 paths for the S&P 500 today
Valeant Pharma (VRX) Reports Q1 EPS of $2.36; Announces CFO Transition
April 29, 2015 6:16 AM EDTValeant Pharma (NYSE: VRX) reported Q1 EPS of $2.36, versus $1.76 reported last year. Revenue for the quarter came in at $2.2 billion, versus $1.89 billion reported last year.
Valeant also announced that Howard B. Schiller has advised the Company of his decision to step down as Chief Financial Officer once a successor is appointed. In order to facilitate a smooth transition, Mr. Schiller will remain in his current position as the search for his replacement proceeds. With the support of Valeant's Board of Directors, Mr. Schiller will remain on the Valeant Board and, with the Board's continued... More
